{"filing":{"accession_number":"0001193125-26-265835","cik":"0001678660","ticker":"PRLD","company_name":"Prelude Therapeutics Inc","form":"8-K","filing_date":"2026-06-10","report_date":null,"primary_document":"prld-20260609.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1678660/000119312526265835/prld-20260609.htm"},"events":[{"id":5652,"run_id":4955,"accession_number":"0001193125-26-265835","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a classic Item 5.07 disclosure reporting the results of Prelude Therapeutics' 2026 Annual Meeting of Stockholders held on June 9, 2026. The filing presents voting results for four proposals: election of three Class III directors (Krishna Vaddi, Paul Scherer, and Katina Dorton), ratification of Ernst \u0026 Young LLP as independent auditor, advisory vote on named executive officer compensation, and advisory vote on the frequency of compensation votes. All proposals were approved by stockholders, with detailed vote tallies provided for each nominee and proposal.","company_name":"Prelude Therapeutics Inc","ticker":"PRLD","filing_date":"2026-06-10","form":"8-K","submitted_at":null,"items":[{"id":5847,"accession_number":"0001193125-26-265835","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of Prelude Therapeutics' 2026 Annual Meeting of Stockholders held on June 9, 2026. The filing presents voting results for four proposals: election of three Class III directors (Krishna Vaddi, Paul Scherer, and Katina Dorton), ratification of Ernst \u0026 Young LLP as independent auditor, advisory vote on named executive officer compensation, and advisory vote on the frequency of compensation votes. All proposals were approved by stockholders, with detailed vote tallies provided for each nominee and proposal.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T20:12:16.414753+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5847,"accession_number":"0001193125-26-265835","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of Prelude Therapeutics' 2026 Annual Meeting of Stockholders held on June 9, 2026. The filing presents voting results for four proposals: election of three Class III directors (Krishna Vaddi, Paul Scherer, and Katina Dorton), ratification of Ernst \u0026 Young LLP as independent auditor, advisory vote on named executive officer compensation, and advisory vote on the frequency of compensation votes. All proposals were approved by stockholders, with detailed vote tallies provided for each nominee and proposal.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T20:12:16.414753+00:00","company_name":"Prelude Therapeutics Inc","ticker":"PRLD","filing_date":"2026-06-10"}]}